Skip to main content
AAN.com
Editorial
August 1, 2019

Screening with a high-precision blood-based assay for Alzheimer disease

October 22, 2019 issue
93 (17) 737-738

Abstract

The use of biomarkers for defining the pathobiology of Alzheimer disease (AD) has had a transformative effect on the field, facilitating disease detection prior to autopsy, as well as substantially altering clinical trial design.1 In the last 5–10 years, there has been a substantial shift toward using amyloid PET in human research, as well as clinically, to rule out AD (a negative scan meaning little or no plaque is present). Likewise, obtaining a sample of CSF via lumbar puncture provides a plethora of information on amyloid plaque burden, tau pathology, neurodegeneration, and gliosis. While amyloid PET and CSF β-amyloid (Aβ)42/Aβ40 have excellent diagnostic accuracy, and correspond well with plaque burden measured postmortem,2 it is widely recognized that access to a simple blood test for AD would change the field yet again.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Knopman DS, Petersen RC, Jack CR Jr. A brief history of “Alzheimer disease”: multiple meanings separated by a common name. Neurology 2019;92:1053–1059.
2.
Cohen AD, Landau SM, Snitz BE, Klunk WE, Blennow K, Zetterberg H. Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. Mol Cell Neurosci 2019;97:3–17.
3.
Hampel H, O'Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 2018;14:639–652.
4.
Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry 2002;159:738–745.
5.
Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 2019;93:e1647–e1659.
6.
Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's disease. Alzheimer's Res Ther 2019;11:34.
7.
Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 2017;13:841–849.
8.
Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-beta biomarkers for Alzheimer's disease. Nature 2018;554:249–254.
9.
Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019;321:1286–1294.

Information & Authors

Information

Published In

Neurology®
Volume 93Number 17October 22, 2019
Pages: 737-738
PubMed: 31371570

Publication History

Published online: August 1, 2019
Published in print: October 22, 2019

Permissions

Request permissions for this article.

Disclosure

B. Bendlin has received precursors and imaging agents from Avid Radiopharmaceuticals. H. Zetterberg is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg, has served on scientific advisory boards for Roche Diagnostics, Samumed, CogRx, and Wave, and has given lectures in symposia sponsored by Biogen and Alzecure. Go to Neurology.org/N for full disclosures.

Study Funding

No targeted funding reported.

Authors

Affiliations & Disclosures

Barbara B. Bendlin, PhD
From the Wisconsin Alzheimer's Disease Research Center (B.B.B.), University of Wisconsin School of Medicine and Public Health, University of Wisconsin–Madison; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry (H.Z.), Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), University College London Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
Serving as a member of a data safety monitoring board for project R21AG056882, "Network-Level Mechanisms for Preclinical Alzheimer?s Disease Development", PI: Shi-Jiang Li.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer's Disease; Associate Editor; term ending 12/31/2020
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
1. Precursor and imaging agents from Avid Radiopharmaceuticals.
Research Support, Government Entities:
1.
1. SV2A PET imaging in Alzheimer's Disease 09/30/2018-5/31/2023 NIH R01AG062285, National Institute on Aging Role: PI (MPI) 2. Neighborhood Socioeconomic Contextual Disadvantage and Alzheimer's Disease 09/15/2017 - 06/30/2022 RF1AG057784, National Institute on Aging (NIA) Role: PI (MPI) 3. White matter degeneration: biomarkers in preclinical Alzheimer's disease 9/15/2017-08/31/2019 (NCE) R56AG037639, National Institute on Aging (NIA) Role: PI 4. Alzheimer's Disease Connectome Project 04/01/2016 - 03/31/2020 UF1AG051216, National Institute on Aging (NIA) Role: PI (MPI) 5. Wisconsin Alzheimer?s Disease Research Center 4/1/2019-3/31/2024 P50 AG033514, National Institute on Aging Asthana, Sanjay (PI) Role: Co-Investigator 6. Algebraic Formulations for Characterizing Structural Brain Connectivity Changes and Pathology Transmission Networks in Preclinical Alzheimer?s Disease 09/01/2018-08/31/2023 R01AG059312, National Institute on Aging (NIA) Role: PI (MPI)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Henrik Zetterberg, MD, PhD
From the Wisconsin Alzheimer's Disease Research Center (B.B.B.), University of Wisconsin School of Medicine and Public Health, University of Wisconsin–Madison; Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry (H.Z.), Sahlgrenska Academy at University of Gothenburg; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), University College London Institute of Neurology; and UK Dementia Research Institute at UCL (H.Z.), London, UK.
Disclosure
Scientific Advisory Boards:
1.
HZ has served at advisory boards for Roche Diagnostics, Samumed, CogRx and Wave.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer's Disease, Associate Editor Alzheimer's & Dementia, Associate Editor DADM, Associate Senior Editor Molecular and Cellular Neuroscience, Editor Scandinavian Journal of Clinical and Laboratory Investigation, Editor
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
HZ is co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg.
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) Swedish State Support for Clinical Research (ALFGBG- 144341) and (2) the Knut and Alice Wallenberg Foundation
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. Bendlin [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Amyloid β aggregation induces human brain microvascular endothelial cell death with abnormal actin organization, Biochemistry and Biophysics Reports, 29, (101189), (2022).https://doi.org/10.1016/j.bbrep.2021.101189
    Crossref
  2. Commonalities between Copper Neurotoxicity and Alzheimer’s Disease, Toxics, 9, 1, (4), (2021).https://doi.org/10.3390/toxics9010004
    Crossref
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share